ArticleDiscover oncology2026
Epigenetic remodeling and apoptotic activation by Chidamide suppress small cell lung cancer in molecularly distinct subtypes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Small cell lung cancer (SCLC), known for its aggressive nature and resistance to treatment, continues to evade effective targeted therapies. This study investigates the therapeutic potential of Chidamide, a subtype-selective histone deacetylase inhibitor (HDACi), in molecularly distinct SCLC models. In vitro, Chidamide showed dose- and time-dependent cytotoxicity across SCLC-A/N/P subtypes (H69, H526, H446), inhibiting proliferation (IC50: 1.979–4.9 μM) and clonogenicity (P < 0.001). It also caused G1/S arrest by increasing p21/p27 levels and decreasing Cyclin E1/CDK2 expression. Mechanistically, Chidamide elevated overall histone H3/H4 acetylation by inhibiting HDAC1/2/3, triggered γ-H2AX-associated DNA damage, and activated mitochondrial apoptosis. Flow cytometry confirmed dose-dependent apoptosis induction (12.45–43.03% across cell lines) and G1-phase accumulation (up to 61.8% in H69). In vivo, oral Chidamide (12.5–25 mg/kg) significantly inhibited xenograft tumor growth, aligning with increased histone acetylation, p21 expression, and Cleaved caspase-3 in treated tumors. Collectively, these results position Chidamide as a promising epigenetic candidate for SCLC therapy, demonstrating preclinical efficacy across molecular subtypes through modulation of chromatin architecture and DNA damage response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.